The Food and Drug Administration on Friday approved marketing of the Merck drug boceprevir, the first new drug for hepatitis C in 20 years. The agency is still considering approval of a similar drug, telaprevir, and is expected to approve it soon as well. Both drugs are members of a new class of hepatitis drugs called protease inhibitors, which block a key enzyme required by the virus to replicate.
They are expected to convert hepatitis C from a debilitating disease into a manageable condition for the majority of people infected with the virus. Boceprevir, which will be marketed by Merck under the brand name Victrelis, is approved only for use in conjunction with the current hepatitis C drugs, peginterferon-alpha and ribavirin.
Health Glance
The active ingredient in marijuana cuts tumor growth in common lung cancer in half and significantly reduces the ability of the cancer to spread, say researchers at Harvard University who tested the chemical in both lab and mouse studies.
An HIV-positive person who takes anti-retroviral drugs after diagnosis, rather than when their health declines, can cut the risk of spreading the virus to uninfected partners by 96%, according to a study.
The one bright side of having bed bugs — if you wanted to be really optimistic about it — has always been that at least the tormenting critters didn't transmit disease. But now researchers in Vancouver report that they've found bed bugs with methicillin-resistant Staphylococcus aureus, or MRSA.





























